DOP2023000145A - Inhibidores de cdk2 y métodos de uso de los mismos - Google Patents
Inhibidores de cdk2 y métodos de uso de los mismosInfo
- Publication number
- DOP2023000145A DOP2023000145A DO2023000145A DO2023000145A DOP2023000145A DO P2023000145 A DOP2023000145 A DO P2023000145A DO 2023000145 A DO2023000145 A DO 2023000145A DO 2023000145 A DO2023000145 A DO 2023000145A DO P2023000145 A DOP2023000145 A DO P2023000145A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- cdk2
- cdk2 inhibitors
- inhibitors
- disorders
- Prior art date
Links
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title abstract 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos para la inhibición de CDK2, y el tratamiento de enfermedades y trastornos relacionados con CDK2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143360P | 2021-01-29 | 2021-01-29 | |
| PCT/US2022/070409 WO2022165513A1 (en) | 2021-01-29 | 2022-01-28 | Cdk2 inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000145A true DOP2023000145A (es) | 2023-10-31 |
Family
ID=82654899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000145A DOP2023000145A (es) | 2021-01-29 | 2023-07-27 | Inhibidores de cdk2 y métodos de uso de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230109076A1 (es) |
| EP (1) | EP4284365A1 (es) |
| JP (1) | JP2024505261A (es) |
| KR (1) | KR20230142745A (es) |
| CN (1) | CN117177744A (es) |
| AU (1) | AU2022214618A1 (es) |
| BR (1) | BR112023015210A2 (es) |
| CA (1) | CA3208618A1 (es) |
| CL (1) | CL2023002223A1 (es) |
| CO (1) | CO2023010023A2 (es) |
| CR (1) | CR20230362A (es) |
| DO (1) | DOP2023000145A (es) |
| EC (1) | ECSP23057264A (es) |
| IL (1) | IL304728A (es) |
| MX (1) | MX2023008968A (es) |
| PE (1) | PE20240050A1 (es) |
| TW (1) | TW202239402A (es) |
| WO (1) | WO2022165513A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026486A2 (en) * | 2022-07-28 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024026483A2 (en) * | 2022-07-28 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024026479A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024026481A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3006441A1 (en) * | 2009-09-04 | 2016-04-13 | Janssen Pharmaceuticals, Inc. | Ns5a inhibitors |
| UY33199A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| CA3129516A1 (en) * | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
-
2022
- 2022-01-28 TW TW111104194A patent/TW202239402A/zh unknown
- 2022-01-28 BR BR112023015210A patent/BR112023015210A2/pt unknown
- 2022-01-28 PE PE2023002221A patent/PE20240050A1/es unknown
- 2022-01-28 CR CR20230362A patent/CR20230362A/es unknown
- 2022-01-28 AU AU2022214618A patent/AU2022214618A1/en active Pending
- 2022-01-28 MX MX2023008968A patent/MX2023008968A/es unknown
- 2022-01-28 JP JP2023546536A patent/JP2024505261A/ja active Pending
- 2022-01-28 EP EP22746916.0A patent/EP4284365A1/en active Pending
- 2022-01-28 CA CA3208618A patent/CA3208618A1/en active Pending
- 2022-01-28 US US17/649,269 patent/US20230109076A1/en active Pending
- 2022-01-28 CN CN202280024871.XA patent/CN117177744A/zh active Pending
- 2022-01-28 WO PCT/US2022/070409 patent/WO2022165513A1/en active Application Filing
- 2022-01-28 KR KR1020237029169A patent/KR20230142745A/ko unknown
-
2023
- 2023-07-25 IL IL304728A patent/IL304728A/en unknown
- 2023-07-27 EC ECSENADI202357264A patent/ECSP23057264A/es unknown
- 2023-07-27 DO DO2023000145A patent/DOP2023000145A/es unknown
- 2023-07-27 CL CL2023002223A patent/CL2023002223A1/es unknown
- 2023-07-27 CO CONC2023/0010023A patent/CO2023010023A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304728A (en) | 2023-09-01 |
| AU2022214618A1 (en) | 2023-08-17 |
| CA3208618A1 (en) | 2022-08-04 |
| EP4284365A1 (en) | 2023-12-06 |
| CN117177744A (zh) | 2023-12-05 |
| WO2022165513A1 (en) | 2022-08-04 |
| CL2023002223A1 (es) | 2023-12-29 |
| PE20240050A1 (es) | 2024-01-09 |
| US20230109076A1 (en) | 2023-04-06 |
| MX2023008968A (es) | 2023-09-22 |
| KR20230142745A (ko) | 2023-10-11 |
| JP2024505261A (ja) | 2024-02-05 |
| BR112023015210A2 (pt) | 2023-11-07 |
| CR20230362A (es) | 2023-11-23 |
| ECSP23057264A (es) | 2023-09-29 |
| TW202239402A (zh) | 2022-10-16 |
| CO2023010023A2 (es) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| CO2022001453A2 (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| ECSP22029193A (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
| BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| ECSP20024210A (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CO2020005065A2 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. |